OBJECTIVE: To analyze the enhancement patterns of small renal masses (SRMs) during 4-phase computed tomography (CT) imaging to predict histology. METHODS: One-hundred consecutive patients with SRMs and 4-phase preoperative CT imaging, who underwent extirpative surgery with a pathologic diagnosis of renal cell carcinoma (RCC), angiomyolipoma (AML), or oncocytoma, were identified from a single institution. An expert radiologist, blinded to histologic results, retrospectively recorded tumor size, RENAL (radius, exophytic/endophytic properties of the tumor, nearness of tumor deepest portion to the collecting system or sinus, anterior/posterior descriptor, and the location relative to polar lines) nephrometry score, tumor attenuation, and the renal cortex on all 4 acquisitions (precontrast, corticomedullary, nephrogenic, and delayed density). RESULTS: Pathologic diagnoses included 48 clear-cell RCCs (ccRCCs), 22 papillary RCCs, 10 chromophobe RCCs, 13 oncocytomas, and 7 AMLs. There was no significant difference in median tumor size (P = .8), nephrometry score (P = .98), or anatomic location (P >.2) among histologies. Significant differences were noted in peak enhancement (P <.001) and phase-specific enhancement (P <.007) by histology. Papillary RCCs demonstrated a distinct enhancement pattern, with a peak Hounsfield unit (HU) of 56, and greatest enhancement during the NG and delayed phases. The highest peak HU were demonstrated by ccRCC (117 HU) and oncocytoma (125 HU); ccRCC more often peaked in the corticomedullary phase, whereas oncocytoma peaked in the nephrogenic phase. CONCLUSION: In a series of patients with SRMs undergoing 4-phase CT, tumor histologies demonstrated distinct enhancement patterns. Thus, preoperative 4-phase CT imaging may provide useful information regarding pathologic diagnosis in patients undergoing extirpative surgery.
OBJECTIVE: To analyze the enhancement patterns of small renal masses (SRMs) during 4-phase computed tomography (CT) imaging to predict histology. METHODS: One-hundred consecutive patients with SRMs and 4-phase preoperative CT imaging, who underwent extirpative surgery with a pathologic diagnosis of renal cell carcinoma (RCC), angiomyolipoma (AML), or oncocytoma, were identified from a single institution. An expert radiologist, blinded to histologic results, retrospectively recorded tumor size, RENAL (radius, exophytic/endophytic properties of the tumor, nearness of tumor deepest portion to the collecting system or sinus, anterior/posterior descriptor, and the location relative to polar lines) nephrometry score, tumor attenuation, and the renal cortex on all 4 acquisitions (precontrast, corticomedullary, nephrogenic, and delayed density). RESULTS: Pathologic diagnoses included 48 clear-cell RCCs (ccRCCs), 22 papillary RCCs, 10 chromophobe RCCs, 13 oncocytomas, and 7 AMLs. There was no significant difference in median tumor size (P = .8), nephrometry score (P = .98), or anatomic location (P >.2) among histologies. Significant differences were noted in peak enhancement (P <.001) and phase-specific enhancement (P <.007) by histology. Papillary RCCs demonstrated a distinct enhancement pattern, with a peak Hounsfield unit (HU) of 56, and greatest enhancement during the NG and delayed phases. The highest peak HU were demonstrated by ccRCC (117 HU) and oncocytoma (125 HU); ccRCC more often peaked in the corticomedullary phase, whereas oncocytoma peaked in the nephrogenic phase. CONCLUSION: In a series of patients with SRMs undergoing 4-phase CT, tumor histologies demonstrated distinct enhancement patterns. Thus, preoperative 4-phase CT imaging may provide useful information regarding pathologic diagnosis in patients undergoing extirpative surgery.
Authors: Andrea J Ruppert-Kohlmayr; Martin Uggowitzer; Thomas Meissnitzer; Georg Ruppert Journal: AJR Am J Roentgenol Date: 2004-11 Impact factor: 3.959
Authors: Brian R Herts; Deirdre M Coll; Andrew C Novick; Nancy Obuchowski; Grant Linnell; Susan L Wirth; Mark E Baker Journal: AJR Am J Roentgenol Date: 2002-02 Impact factor: 3.959
Authors: Steven C Campbell; Andrew C Novick; Arie Belldegrun; Michael L Blute; George K Chow; Ithaar H Derweesh; Martha M Faraday; Jihad H Kaouk; Raymond J Leveillee; Surena F Matin; Paul Russo; Robert G Uzzo Journal: J Urol Date: 2009-08-14 Impact factor: 7.450
Authors: S Störkel; J N Eble; K Adlakha; M Amin; M L Blute; D G Bostwick; M Darson; B Delahunt; K Iczkowski Journal: Cancer Date: 1997-09-01 Impact factor: 6.860
Authors: M Jinzaki; A Tanimoto; M Mukai; E Ikeda; S Kobayashi; Y Yuasa; Y Narimatsu; M Murai Journal: J Comput Assist Tomogr Date: 2000 Nov-Dec Impact factor: 1.826
Authors: Jeong Kon Kim; Tae Kyoung Kim; Han Jong Ahn; Chung Soo Kim; Kyu-Rae Kim; Kyoung-Sik Cho Journal: AJR Am J Roentgenol Date: 2002-06 Impact factor: 3.959
Authors: Alexander Kutikov; Marc C Smaldone; Brian L Egleston; Brandon J Manley; Daniel J Canter; Jay Simhan; Stephen A Boorjian; Rosalia Viterbo; David Y T Chen; Richard E Greenberg; Robert G Uzzo Journal: Eur Urol Date: 2011-04-01 Impact factor: 20.096
Authors: Ghazi Alshumrani; Martin O'Malley; Sangeet Ghai; Ur Metser; John Kachura; Antonio Finelli; Kamal Mattar; Tony Panzarella Journal: Abdom Imaging Date: 2009-06-18
Authors: Shaheed W Hakim; Nicola Schieda; Taryn Hodgdon; Matthew D F McInnes; Marc Dilauro; Trevor A Flood Journal: Eur Radiol Date: 2015-06-03 Impact factor: 5.315
Authors: Andreas M Hötker; Yousef Mazaheri; Andreas Wibmer; Christoph A Karlo; Junting Zheng; Chaya S Moskowitz; Satish K Tickoo; Paul Russo; Hedvig Hricak; Oguz Akin Journal: AJR Am J Roentgenol Date: 2017-01-17 Impact factor: 3.959
Authors: Jay Amin; Bo Xu; Shervin Badkhshan; Terrance T Creighton; Daniel Abbotoy; Christine Murekeyisoni; Kristopher M Attwood; Thomas Schwaab; Craig Hendler; Michael Petroziello; Charles L Roche; Eric C Kauffman Journal: Clin Cancer Res Date: 2018-05-11 Impact factor: 12.531
Authors: Akrita Bhatnagar; Steven P Rowe; Michael A Gorin; Martin G Pomper; Elliot K Fishman; Mohamad E Allaf Journal: J Comput Assist Tomogr Date: 2016 Jul-Aug Impact factor: 1.826